Calypte und die Zeit nach AIDS2004 in Bangkok

 

 

 

Pre-Market Trade Reporting Tuesday October 5  -->Pre-Market
Last:-->$0.42 Pre-Market
Best Bid:N/A -->Pre-Market
High:-->$0.42-->Pre-Market
Volume:-->700 Pre-Market
Best Ask:N/A -->Pre-Market
Low:-->$0.42Pre-Market
Time (ET)Pre-Market
PricePre-Market
Share Volume08.59$ 0.42700

 

CIAO

 

 

bin mal seit heute wieder mit 'nen paar Tsd. bei euch zu 0,33.

Hoffe auf schnelle 20%, schaun wir mal.

Wie geht's denn sonst so? Noch alles fit bei Euch?

Grüße, ZN  

Calypte Biomedical Announces Licensing Agreement with Ani Biotech

   Agreement gives company worldwide freedom to operate for its rapid HIV
                                  platform
PLEASANTON, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has entered into a worldwide licensing technology transfer and equipment purchase agreement with Ani Biotech (Ani). The agreement grants Calypte access to Ani's new patent pending rapid diagnostic test platform and sample applicator technology. In consideration for the worldwide license, Ani will receive a license fee and future royalties based upon sales in the worldwide professional and OTC human in-vitro diagnostic testing markets.

Under the terms of the agreement, Calypte has been granted an exclusive license to develop, manufacture and sell rapid diagnostic tests for several sexually transmitted diseases (STDs), including HIV, HPV, Hepatitis B, Hepatitis C, Syphilis, Gonorrhea, and Chlamydia when urine or oral fluid are the sample media. Calypte has also been granted a non-exclusive license to develop, manufacture and sell the same STD diagnostic tests when blood, serum, plasma, or urogenital swabs are the sample media.

Dr. Richard George, Calypte's CEO stated, "Prior to this agreement, the Company's Intellectual Property rights precluded us from pursuing the commercialization of our rapid HIV testing platform in the United States, Europe and Japan. As a result, the Company focused on launching its suite of rapid HIV diagnostic tests into Sub-Saharan Africa and China. We believe that this milestone agreement grants us the ability to compete on a global basis and concludes our Intellectual Property licensing efforts for the rapid lateral flow platform. With this agreement, we expect to expand our commercial pursuits to the US, European and Japanese markets." Dr. George added, "We believe that the real upside of this agreement is our ability to expand our focus from HIV to the diagnosis of a broader range of sexually transmitted diseases."

Dr. Aimo Niskanen, CEO of Ani Biotech stated, "We view our agreement with Calypte as a major triumph in the battle against diagnosing STDs, especially the detection of HIV. Calypte's leadership in the field of HIV gives it the technical and scientific ability to expand into testing for other STDs, and together with Ani's rapid diagnostic test technology platform, a simple and reliable alternative to testing procedures that, until now, have been restricted to a laboratory or clinical setting."

As a result of this agreement, the Company expects to commence development of STD diagnostic tests, the first being HIV, using the new rapid test platform and sample applicator technology, no later than in the first half of 2005. The Company also expects to begin the regulatory process for professional and OTC market clearance with the U.S. Food and Drug Administration (FDA) in late 2005. In conjunction with these initiatives, Calypte will utilize its current FDA approved manufacturing facility in Rockville, MD to manufacture these emerging STD rapid diagnostic tests.

According to the report by the Centers for Disease Control and Prevention (CDC) titled Tracking the Hidden Epidemics -- Trends in STDs in the United States, more than 65 million people in the US are currently living with an incurable STD (of which approximately 10% is HIV), and another 15 million people annually become infected with an STD. Aside from HIV infection, STDs are one of the most under-recognized health problems in the US today. Despite the fact that STDs are extremely widespread, have severe and sometimes deadly consequences, and add billions of dollars to the nation's healthcare costs each year, most people in the US remain unaware of the risks and consequences of all but the most publicized STD -- HIV.

A conference call will be held to review this agreement later today at 11 am EDT. The call can be accessed in the U.S. by dialing 866-800-8652 and outside of the U.S. by dialing 617-614-2705 and entering conference identification number 12233446. The conference call will also be webcast live at http://www.calypte.com. An audio replay of the call will be available beginning October 6, 2004 until December 12, 2004 by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The conference identification number is 17966811. The replay will also be available on http://www.calypte.com .

About Ani Biotech:

Ani Biotech is a clinical diagnostic company producing diagnostic test kits and reagents for laboratory, physician office and home use. Ani is privately owned, and part of a group of companies all active in the healthcare sector. Ani Biotech is headquartered in Helsinki, Finland.

About Calypte Biomedical:

Calypte Biomedical Corporation, headquartered in Pleasanton, California, is a healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 Incidence EIA as well as tests that can determine HIV antibody status without the need for blood. Calypte is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2003 and its subsequent filings with the SEC.

    Company Contact:                    Investor Relations Contact:
    Richard George, CEO                 Tim Clemensen,
    (925) 730-7200                      Rubenstein Investor Relations
    email: rgeorge@calypte.com          Phone: (212) 843-9337
                                        email: tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical Corporation
   -0-                             10/05/2004
   /CONTACT:  Richard George, CEO of Calypte Biomedical Corporation,
+1-925-730-7200, rgeorge@calypte.com; or Tim Clemensen of Rubenstein Investor
Relations, +1-212-843-9337, tclemensen@rubensteinir.com, for Calypte
Biomedical Corporation/
   /Web site:  http://www.calypte.com /
   (HIV)

CO:  Calypte Biomedical Corporation; Ani Biotech
ST:  California
IN:  HEA BIO MTC
SU:  LIC CCA

LI
-- NYTU003B --
3194 10/05/2004 10:30 EDT http://www.prnewswire.com

 

Hat Caly nun ein Exclusivrecht!  

Hat Caly nun ein Exclusivrecht!  

warmduschernews. scheinbar sind die meisten amis schlauer als die deutschen.

solange die zulassung der WHO nicht vorliegt und KEINE UMSÄTZE SPRICH GROSSAUFTRÄGE REINKOMMEN wird sich hier immer nur sehr kurzfrisitg etwas tun.

da könnt ihr die notwendigkeit solcher test propagieren wie ihr wollt und noch so sehr an die ethik und moral appellieren...es wird euch nichts helfen. caly ist und bleibt bis zu den großen umsätzen bzw. großaufträgen eine aktiendruckfirma, sonst nichts.

im übrigen würde caly nur dann aids bekämpfen, wen sie ein gegenmittel gegen aids herstellen würden oder condome. wenn der test "positv" anzeigt, ist es zu spät...


CALYPTE BIOMEDICAL - : HIV

Time & Sales most recent  next page
Rec. Time Action Price Volume
10:34:54 AM Ask 0.41  13400  
10:34:54 AM Ask 0.41  8400  
10:34:54 AM Trade 0.41  2000  
10:34:46 AM Ask 0.41  15500  
10:34:46 AM Trade 0.41  7100  
10:34:42 AM Bid 0.4  32900  
10:34:42 AM Bid 0.4  10000  
10:34:42 AM Ask 0.41  17500  
10:34:42 AM Trade 0.41  3000  
10:34:28 AM Trade 0.41  2000  
10:34:26 AM Trade 0.41  1000  
10:34:20 AM Trade 0.41  1000  
10:34:20 AM Trade 0.41  1000  
10:34:10 AM Trade 0.41  5200  
10:34:04 AM Bid 0.41  7100  
10:34:04 AM Trade 0.41  1000  
10:34:04 AM Trade 0.41  1000  
10:34:02 AM Trade 0.41  1000  
10:34:02 AM Trade 0.41  1000  
10:33:54 AM Bid 0.41  12300  
10:33:54 AM Trade 0.42  800  
10:33:54 AM Trade 0.42  800  
10:33:52 AM Ask 0.42  162200  
10:33:52 AM Ask 0.42  163000  


 

ein "non-exclusive" recht..."...has entered into a worldwide, non-exclusive licensing agreement with Bio-Rad Laboratories..."  

Exclusiv für Speichel und Urin! NON Exclusiv für Blut ect.!  

alle test, egal welche, die auch hiv-2 diagnostizieren können, werden NICHT-exklusiv durch bio-rad vertrieben. ließ dir die meldung nochmal genau durch.

die exklusivität für deinen tollen urintest, der aber nur hiv-1 erkennen kann, kannst getrost in die tonne treten...  

A Form 8-K regarding Calypte Biomedical Corp. has been filed with the United States Securities and Exchange Commission.

To view this filing, please click here  http://www.calypte.com/INV/INV_HOME.html
 _____  

If you are unable to click on the link above, please copy and paste the URL below into a web browser
http://www.calypte.com/INV/INV_HOME.html
Click Here  to unsubscribe from this JoinMail list.  

keine Kurssteigerungen, also warte ich weiter.

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

arbeit.

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

sprüchlein aus dem august kopieren:

"...die aussichten sind wie immer glänzend...    joelu  12.08.04 18:08"


aber lucky, und das ist sehr wichtig, dafür ziehe ich den hut vor dir:

du hast keine aufträge erwartet!!!!!!! das klang vor ein paar wochen noch anders!!! beim letzten CC sind euch doch sogar noch welche für den august versprochen worden. du erinnerst dich????

lucky, langsam kehrst du zum realismus zurück, vielleicht die illusion, die ihr alle habt, irgendwann dann doch noch dem weitblick für cataldo und seine krummen machenschaften...    

arbeit abnehmen. hier 2 statements aus dem RB-board. ich denke nich dass caly2zero lügt, auch wenn er zusammen mit roy_hinkley, der amerikanische joelu ist (lach, prust)

59610          As I said Gumby...clinicals in China have not star caly2zero
05 Oct 2004 11:26 AM EDT


59611          As I said Gumby...no rpaid sales in 04...per Dr. G caly2zero  
05 Oct 2004 11:26 AM EDT


By: caly2zero  
05 Oct 2004, 11:32 AM EDT
Msg. 59619 of 59654
Jump to msg. #  
True...but he did say China 2nd half 05 ..Africa 1st half 05 (doubful as he said Clinicals won't begin until late this year).. Did he mention even one market for rapid sales this year?NO Did he predict rapid sales anywhere this year? NO


...und eure dilution geht weiter:

By: caly2zero  
05 Oct 2004, 11:33 AM EDT
Msg. 59620 of 59654
Jump to msg. #  
3.75 million additional share dilution for ANI deal  



 

Wie gehts eigentlich deinen Werten. Ich hoffe du verschwendest für diese mindestens genauso viel Zeit wie für Calypte, wobei das kaum möglich ist.

 

By: caly2zero  
05 Oct 2004, 11:39 AM EDT
Msg. 59630 of 59654
Jump to msg. #  
Billy..From Dr. George 15 minutes ago.. Formal Clinicals in China have not even started yet! FACT


aber auch das!!!!!!!!!!!!!!!

By: billblueyz  
05 Oct 2004, 11:43 AM EDT
Msg. 59633 of 59654
(This msg. is a reply to 59630 by caly2zero.)
Jump to msg. #  
boy you really dont listen he said although they have not started they will soon be started and completed by end of 2004


By: caly2zero  
05 Oct 2004, 11:45 AM EDT
Msg. 59636 of 59654
Jump to msg. #  
And they said last year they would have rapid sales late '03...then first half '04... then 2nd half '04...and today the qoute is "cHina in 2nd half '05.. Why would you believe anything they say about time lines?


By: roy_hinkley  
05 Oct 2004, 11:46 AM EDT
Msg. 59637 of 59654
Jump to msg. #  
HIV gotta be getting low on cash and stock presently under the "threshold" number of $ .40.

Tony "Mr. Big Dilution" Cataldo at it again.

 

 

du zurück an board. hier noch ein paar statements für dich zum nachvollziehen:

By: caly2zero  
05 Oct 2004, 11:49 AM EDT
Msg. 59638 of 59654
Jump to msg. #  
Cash will be gone by end of Jan. '05 at current burn rate


By: roy_hinkley  
05 Oct 2004, 11:50 AM EDT
Msg. 59643 of 59654
(This msg. is a reply to 59640 by alan_hale_jr.)
Jump to msg. #  
Still calling for rapid sales in 2004 Gumby and PPs at $ 3 by Christmas?...


By: caly2zero  
05 Oct 2004, 11:53 AM EDT
Msg. 59645 of 59654
Jump to msg. #  
Per the CC, the first payment to ani was in stock...1.2 million shares at 40 cents



 

sind  Harn oder Speicher Proben
nicht Exclusiv Blut, "Serum", "Plasma", oder "urogenital Tupfer" Proben.

joelu diese Pasage zeige mir bitte!
"Alle test, egal welche, die auch hiv-2 diagnostizieren können, werden NICHT-exklusiv durch bio-rad vertrieben"

von HIV-2 steht da nix! Oder ich habs überlesen...


Gruß Pate